Highest-materiality recent filing
Strata Skin Sciences to be delisted from Nasdaq on Feb 19 after failing equity requirement
Company failed to meet Nasdaq's minimum $2.5M stockholders' equity; funding efforts unsuccessful.
Strata Skin Sciences Q3 revenue $6.9M (-21% YoY); net loss narrows to $1.6M
Revenue $6.9M (-21% YoY); net loss $1.6M (EPS -$0.36) vs $2.1M loss (EPS -$0.51) last year.
Strata Skin Sciences gains Nasdaq extension to Feb. 16, 2026 for equity compliance
Nasdaq accepted Strata's plan and extended the deadline to Feb. 16, 2026 to meet the $2.5M stockholders' equity requirement.
Strata Skin Sciences prices $2.42M registered direct offering at $2.204/share
Offering of 1,097,547 shares at $2.204 per share, priced at-market under Nasdaq rules.
Nasdaq notified Strata on Aug 19, 2025 of non-compliance with minimum stockholders' equity requirement of $2.5M.
Strata Skin Sciences Q2 revenue down 9% to $7.7M; net loss widens to $2.5M, EPS -$0.60
Revenue $7.7M (down 9% YoY); net loss $2.5M vs $0.1M loss in Q2 2024 (EPS -$0.60 vs -$0.03).
Working with CMS to secure temporary codes for expanded CPT codes for XTRAC, aiming for 2026 reimbursement instead of 2027.
AMA expands CPT codes for SSKN's XTRAC laser; now covers vitiligo, atopic dermatitis, alopecia
AMA CPT Editorial Panel revised codes 96920-96922 to include inflammatory/autoimmune skin diseases beyond psoriasis.
STRATA Skin Sciences Q1 2025 revenue $6.8M up 1%; net loss narrows to $2.4M
Revenue $6.8M (+1% YoY); gross margin expanded 790 bps to 53.5%.
Strata Q4 rev +10% to $9.6M; net loss $4.5M; adj. EBITDA improves to $2.2M in 2024
Q4 2024 revenue $9.6M, up 10% from $8.7M; net loss $4.5M (EPS -$1.18 vs -$1.09).
STRATA Skin Sciences highlights clinical study showing excimer laser superiority over excimer light
Published study from Nippon Medical School shows excimer laser penetrates deeper into hair follicles and activates more melanocyte stem cells than excimer light.
STRATA Skin Sciences Q3 rev $8.8M, first non-GAAP operating profit since 2018
Revenue $8.8M (-1% YoY); recurring revenue $5.4M (+2% YoY); gross margin 60.3% (up from 56.0% YoY).
STRATA Skin Sciences sues LaserOptek, MLS, Pinnacle for false advertising of Pallas lasers
Filed complaint in U.S. District Court for Eastern District of Pennsylvania alleging unfair competition and false advertising under Lanham Act.
STRATA Q2 net loss narrows to $0.1M; revenue +2% to $8.4M; gross margin 58.5%
Net loss of $0.1M ($0.03 per share) vs $3.1M loss in prior year; operating loss cut to $0.5M from $2.0M.
STRATA Skin Sciences Closes $2.1M Direct Offering with Insider Participation
Issued 665,136 shares at $3.16/share for gross proceeds of $2.1 million.
STRATA pre-announces Q2 revenue $8.0M-$8.4M; XTRAC base down, TheraClear X up
Preliminary Q2 2024 total revenue range: $8.0M - $8.4M.
STRATA Skin Sciences regains Nasdaq compliance, avoids delisting
Received notice from Nasdaq on June 24, 2024 that it now satisfies continued listing requirements under Rule 5550(a)(2).
STRATA Skin Sciences Q1 revenue $6.8M (-11% YoY); net loss widens to $3.4M
Revenue $6.8M vs $7.6M YoY; global recurring revenue $4.7M (-10% YoY).
Strata Skin Sciences announces 1-for-10 reverse stock split to regain Nasdaq compliance
Reverse split ratio 1-for-10 effective 11:59 p.m. ET June 6, 2024; trading begins June 7 under same symbol SSKN with new CUSIP 86272A 305.
Strata Skin Sciences Q4 rev $8.7M, net loss $3.8M; FY rev $33.4M, net loss $10.8M
Q4 2023 revenue $8.7M vs $10.6M in Q4 2022; net loss $3.8M ($0.11 EPS) vs $0.2M loss.
On November 13, 2024, Strata Skin Sciences, Inc. (the “Company”) designated its Vice President Finance, John Gillings, as its principal financial officer and principal accounting officer.
Max materiality 0.90 · Median 0.60 · Most common event other_material